J&J Medical Connect
SPRAVATO®

(esketamine)

J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SPRAVATO® (esketamine)

Medical Information

Use in Patients with Comorbid Multiple Sclerosis

Last Updated: 02/11/2026

Summary

  • SPRAVATO is not indicated for the treatment of multiple sclerosis.
  • Clinical studies designed to evaluate the efficacy and/or safety of SPRAVATO in patients with multiple sclerosis have not been performed.
  • Comorbid multiple sclerosis was not an exclusion criterion in the SPRAVATO clinical trial programs.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 03 February 2026 did not identify any relevant citations pertaining to this topic.